Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro  

绿茶多酚表没食子儿茶素没食子酸酯(EGCG)体外对抗乙肝病毒复制的能力(英文)

作　　者：Jing-yao PANG Kui-jun ZHAO Jia-bo WANG Zhi-jie MA Xiao-he XIAO 

机构地区：[1]Clinical Pharmacy Laboratory, Beijing Friendship Hospital, Capital Medical University [2]China Military Institute of Chinese Medicine, 302 Military Hospital [3]Integrative Medicine Center, 302 Military Hospital

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2014年第6期533-539,共7页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：Project supported by the National Commonweal Industry Special Research Foundation of China(No.200807020);the National Natural Science Foundation of China(Nos.30973947 and 81173571)

摘　　要：Although several antiviral drugs and vaccines are available for use against hepatitis B virus （HBV）, hepatitis caused by HBV remains a major public health problem worldwide, which has not yet been resolved, and new anti-HBV drugs are in great demand. The present study was performed to investigate the anti-HBV activity of epigallocatechin- 3-gallate （EGCG）, a natural-origin compound, in HepG2 2.2.15 cells. The antiviral activity of EGCG was examined by detecting the levels of HBsAg and HBeAg in the supematant and extracellular HBV DNA. EGCG effectively suppressed the secretion of HBsAg and HBeAg from HepG2 2.2.15 cells in a dose- and time-dependent manner, and it showed stronger effects at the level of 0.11-0.44 pmol/ml （50-200 μg/ml） than lamivudine （3TC） at 0.87 μmol/ml （200 pg/ml）. EGCG also suppressed the amount of extracellular HBV DNA. The data indicated that EGCG possessed anti-HBV activity and suggested the potential of EGCG as an effective anti-HBV agent with low toxicity.研究目的：乙肝是尚未解决的公众健康问题，需要开发新型抗病毒药物。本研究拟从天然植物绿茶中寻找有效、经济、毒副作用低的抗乙肝病毒药物。创新要点：研究方法：重要结论首次以HepG22．2．15细胞为载体，发现EGCG对乙肝病毒HBsAg、HBeAg和HBVDNA的选择性作用。采用酶联免疫吸附实验（ELISA）检测细胞上清中HBsAg和HBeAg的含量，采用反转录聚合酶链反应（RT-PCR）检测上清和细胞内HBVDNA的含量。EGCG的浓度在0．11～0．44μmol／ml（即50～200μg／ml）的范围内能有效抑制HepG22．2．15细胞中HBsAg和HBeAg的分泌，其效果甚至优于浓度为0．87μmol／ml（即200μg/ml）的拉米夫定（3TC），并且具有时间和剂量依赖性。同时，EGCG也能抑制胞外HBV DNA的表达。研究结果表明，EGCG具有良好抗病毒活性和低毒副作用，有望开发成为一种新的抗病毒药物。

关 键 词：Epigallocatechin-3-gallate Hepatitis B virus （HBV） Antiviral activity HepG2 2.2.15 LAMIVUDINE 

分 类 号：R512.62[医药卫生—内科学]